Laekna Therapeutics’ $61 Million Series D Financing

Davis Polk advised Laekna Therapeutics in the transaction.

Laekna Therapeutics completed its $61 million Series D financing led by CS Capital with support from Worldstar, and Infinity Capital. Yanchuang Capital as the existing investor continued to support Laekna Therapeutics with additional funding.

Laekna Therapeutics is a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases.

The Davis Polk corporate team included partners Yang Chu (Picture) and Xuelin (Steve) Wang, associates and registered foreign lawyers Michael Zhuoran Xu and Iris Li.

Involved fees earner: Yang Chu – Davis Polk & Wardwell; Iris Li – Davis Polk & Wardwell; Xuelin Wang – Davis Polk & Wardwell; Michael Zhuoran Xu – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Laekna Therapeutics;